NCT06603142View on ClinicalTrials.gov

Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

636

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Primary GoutHyperuricemia
Interventions
DRUG

Febuxostat 20MG Tablets

Febuxostat 20MG Tablets

DRUG

Febuxostat 20MG Placebo

Febuxostat 20MG Placebo

DRUG

AR882 25MG

AR882 25 MG Capsules

DRUG

AR882 12.5MG

AR882 12.5 MG Capsules

DRUG

AR882 25MG Placebo

AR882 25MG Placebo

DRUG

AR882 12.5MG Placebo

AR882 12.5MG Placebo

DRUG

Febuxostat 40MG Tablets

Febuxostat 40MG Tablets

DRUG

Febuxostat 40MG Placebo

Febuxostat 40MG Placebo

Trial Locations (1)

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing

Sponsors
All Listed Sponsors
lead

Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd

INDUSTRY

NCT06603142 - Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia | Biotech Hunter | Biotech Hunter